Complex therapy method for treating children for severe mucoviscidosis
SUBSTANCE: method involves introducing ozonized physiologic saline once a day during 30 min in addition to traditionally applied drugs. The ozonized solution has ozone in concentration of 100-150 mcg/l in the amount of 100-150 ml when treating children younger than 3 years. Children being elder then 3 years, ozone concentration is 200-250 mcg/l, its amount is 200-250 ml. The total therapy course is 5 days long. The traditionally applied drugs are not to be used within 30 min before and after ozonized physiologic saline application.
EFFECT: accelerated treatment course; no antibiotics being used; reduced risk of adverse side effects.
The invention relates to medicine, namely to Pediatrics.
Common treatment option for cystic fibrosis in the period of exacerbation is the use of mucolytic agents, enzymes and kinesitherapy with the mandatory inclusion in basic therapy intravenous courses of antibiotics (Kapranov NI cystic Fibrosis in children. 2003, 76 S.).
The disadvantage is that traditional treatment involves aggressive and prolonged antibiotic therapy in the absence of radically affecting the main pathogenetic syndromes (hypoxemia and tissue hypoxia) components.
In Pediatrics, the known methods of application of ozone therapy in children with appendicular peritonitis (Shamsiev A.M., Yusupov S.A., Atakulov D.O. and other Ozone therapy in the prevention and treatment of postoperative abscesses of the abdominal cavity in children // Children. surgery, 2001, No. 2. P.10-12) and in the treatment of duodenal ulcers (Shamsiev A.M., Yuldashev B.A. the Effectiveness of ozone therapy in children treatment of duodenal ulcers associated with Helicobacter pylori infection, " Vestn. physician General practice, 1997, No. 2, p.7-10).
However, in children suffering from cystic fibrosis, a method of ozone therapy has not previously been used.
The technical result of our invention is to improve the efficiency of complex treatment.
The technical result is achieved by the fact that advanced in trevenna, within 30 minutes, after 30 minutes after the introduction of basic medicines, patients under the age of 3 years is introduced ozonated solution, the concentration of ozone 100-150 µg/l when the volume of injectate 100-150 ml, once a day, a course of 5 days, children older than 3 years, 30 minutes after intravenous administration of traditional medicines, within 30 minutes you enter the ozonized solution with a concentration of ozone 200-250 µg/l when the volume of injectate 200-250 ml, once a day course of 5 days.
The method is as follows. Preparation of the applied solution of ozone for intravenous use is carried out by passing (sparging) kislorodoterapii mixture through a physiological solution. We used for these purposes, the device with a low concentration and ozone destructor AOT-N-01-AR THE 9444-001-075-13518-97. Certificate N ROSS RV, ME34, W. - children up to 3 years after 30 min after the intravenous administration of traditional medicines, for 30 min being ozonated solution in the amount of 100-150 ml with ozone concentration of 100-150 µg/l, 1 times a day, a course of 5 days.
Children older than 3 years after 30 min after the intravenous administration of traditional medicines, for 30 min being ozonated solution with ozone concentration of 200-250 µg/l when the volume of injectate 200-250 ml, once a day, the URS 5 days.
Given the strong oxidizing power of ozone, for intravenous use was observed following rules: drugs for 30 min prior to the introduction of ozone and 30 minutes after application of ozonized solutions were not used. The ozone therapy was carried out for 30 min, because this time its half-life.
Monitoring the effectiveness of ozone therapy was conducted in clinical settings: the reduction and normalization of temperature; the improvement of health, the positive dynamics of physical findings in the lungs; the change of gas composition of blood; the achievement of remission occurred on average 3-4 days earlier than patients receiving standard therapy.
Example No. 1. Patient T., born in 2001, case history No. 4035, was hospitalized in the CSTO No. 2 2.06.2004, - 9.06.2004,
Diagnosis: cystic Fibrosis, mixed, severe, acute. Chronic deforming bronchitis. Pulmocare. Emphysema. Malabsorption syndrome and maldigestion. Functional bowel disorders. GIT. Secondary immunodeficiency. Emerging pulmonary heart. Chronic Pseudomonas aeruginosa infection.
She is seen and treated in the cystic fibrosis center of Voronezh for 4 years. The diagnosis of cystic fibrosis was set at the age of 4.5 months, the disease was manifested respiratory syndrome (bronchitis, pneumatic the AI from birth), delay in physical development, steatorrhea. The diagnosis was confirmed clinically, radiographically, laboratory (chlorides sweat - 70 mmol/l).
From the anamnesis it is known that a girl born from a middle-aged parents (mother was 36 years old, father - 34 years). Pregnancy II, proceeding with preeclampsia in the second half, childbirth I, in time, by caesarean section (I pregnancy - med. abortion, after which for a long time the mother had been treated for infertility).
The girl was born weighing 3600 kg, an increase of 53 see To his chest was applied on 4 days, on breastfeeding were up to 7 days, after that received artificial feeding. Discharged from the hospital for 21 days. It was noted colorless, decorated chair with oily luster, bad otstiryvayutsya from the cradle, rich, 4-5 times per day.
At 1 year of life was seen by the neurologist about perinatal encephalopathy. 1 year weight was 8 kg (mass deficit amounted to 35%).
Hereditary anamnesis: the mother - chronic bronchitis, anemia; father - sinusitis.
Last exacerbation in pneumonic type - may 2004 - required inpatient care. The girl was conducted the following laboratory tests:
Complete blood count: HB 128 g/l; L - 5,8×109/l; P - 2%C - 34%; E. - 1%; l - 59%; m - 4%; ESR - 26 mm/h
Urinalysis - without a pathology.
Chest x-ray - pneum is of S 4-5 right on the background obstructive syndrome.
Biochemical blood test: free. bilirubin - 9,5; thymol Ave - 9,3 ed; B - 203; ASAT - 89; total protein and 64.3 g/l; CRP - 2; glucose of 3.28 mmol/l; amylase - 2,02 mg/CL; urea - 2.3 mmol/l; sialic acid - 2.68 mmol/l; creatinine - 0.035 mmol/L.
ECG: HR - 114 min, sinus rhythm, vertical EOS. Signs of overload of the right ventricle: broadening Z.R. in the II century resp. and V1; V2.
A swab from the throat and nose in U.S. Pat. flora of the throat and nose is dedicated mushrooms p. Candidae, bacteria Ps. aeruginosa and St. aureus.
Ultrasound GPDS: signs of hepatomegaly. Liver: other share - 9.8 cm, lion. share - 4,0 see the Contour smooth, homogeneous structure, drawing anti-aliased. Echo is increased. Spleen 6.8 cm × 2.4 cm - structure is homogeneous, hyperechoic line striated. Kidney without pathology.
Coprogram: slime - moderately; lake. - 4-5 p/SP.; epithelium - 1-2; starch uncle. (++), nutrilett. (+); mysen. fiber (+); fiber parivar. (+); neutral fat (++); detritus (+); microbes (+).
KOS - pH - 7,31 mm RT. Art.; pO234,8; RNO2- 44,4; BE -(-4,4) me/l; AB - 21,7 me/l; total CO2- 23,0 me/l;2sat. - 60,3%.
The girl received the following treatment: CREON 10 thousand to 6 caps./day, maxipime, Fortum, aminophylline, Lasolvan, Ambroxol, ATT, multivitamins, Ursofalk, Viferon, nystatin, CA gluconate, laser therapy for gr. CL No. 7, inhalation via nebulizer with berodual, intravenous infusion of ozonated f is srestore 100,0, with ozone concentration of 100 µg/l, the rate of 5 days. Ozone solutions were introduced in half-hour time interval from the completion of the introduction of the other components of the infusion, 30 minutes, 1 time a day. Adverse reactions when using ozonated solutions were noted.
Amid conducted comprehensive therapy using intravenous ozone therapy temperature normalized on day 2 of treatment, in the same period, significantly improved health; on the 3rd day of treatment decreased the amount of catarrhal phenomena in the lungs, decreased the degree DN.
After 5 days, i.e. after completion of the course of ozone therapy, significantly improved the performance of blood gas composition: pH - 7,34 mm Hg; pO2-71,4; pCO2- 35,7; BE - (-5,4) me/l; AB - 19,1 me/l; total CO2- 20,1 me/l; O2sat. - 93.1% (see table) and hemogram: HB 128 g/l; L - 5,4 × 109/l; P - 2%; With 56%; E. - 1%; l - 37%; m - 4%; ESR - 12 mm/h
In the complete blood count erythrocyte sedimentation rate decreased to 12 mm/h
On the 7th day of treatment taking into account the stable positive dynamics of clinical and laboratory parameters girl was discharged home. Thus, in a child with severe hypoxemia after 5 days of ozone therapy significantly improved KOS, therefore, stabilized homeostasis, decreased the degree of tissue hypoxia.
Example No. 2. Patient M., born in 1994 extract from a case history No. 2216. hospitalizatio in the Center of cystic fibrosis from June 8 to June 16, 2004
The patient was treated with a diagnosis of cystic Fibrosis, mixed, severe. Chronic bronchitis, exacerbation of bronchopulmonary process pneumonic type, DN. Secondary hepatitis. Emerging pulmonary heart. The lag in physical development.
From the anamnesis it is known that the girl from 1 pregnancy occurring with preeclampsia 1 half against the background of anemia, urogenital candidiasis, was born at term with a weight of 2800, height 50 see behavioral development in accordance with age. It was noted poor gain in body weight, and in the year of underweight was 30%. At an early age repeatedly endured severe pneumonia complicated by pneumothorax. The diagnosis of cystic fibrosis is set at the age of 5 months on the basis of the clinic and the performance of the sweat chloride 95 mmol/l Every 3 months the patient was conducted courses of preventive therapy with intravenous infusions of antibiotics.
Last exacerbation in June 2004 Complaints about constant cough with viscous sputum, loss of appetite, undigested copious stools, flatulence. The state of admission heavy, sharply suffers health. The girl lowered food, lack of mass 5 kg High fever, temperature "candle" to 39 degrees. The pale skin, increased sweating. The breathing frequency was 54 per minute. Nasal breathing is difficult, if the IMS-purulent discharge. The chest is barrel-shaped deformation of the distal phalanges of the type "drum sticks". Auscultation of breath hard, fine bubble moist rales in all lung fields. HR 120 minutes auscultation of the heart sounds are muffled, soft systolic murmur at the point of projection of the aorta and at the top. Abdomen slightly increased in size, soft, painless, liver +1 see the Chair unstable, mixed with fat and pungent smell. Survey data at entry:
1. General. an. blood HB - 110 g/l, er. - 3,7, L - 11,1; p/I - 7%, 54%, e - 2%, l - 33%, m 2%, ESR - 18 mm/h
2. B/chemistry blood - O.B. 57 g/l, glucose of 4.4 mmol/l, amylase 27,
3. KOS and blood gases: pH 7,44, pO2- 50, RNO2- 44, BE - (-1,7), AB - 23,8, saturated oxygen - 89.
4. The sputum is selected Pseudomonas aeruginosa.
5. ECG sinus tachycardia, signs of overload of the right ventricle, p puimonale in the right chest leads.
6. Respiratory function: FEV1-55%, FVC-57%, MO-103. Conclusion combined form ventiljacionnoe failure, with a predominance of obstructive.
7. Ultrasound of internal organs: increased size of the liver parenchyma of the pancreas sealed, non-uniform.
Treatment. Intravenous infusion of amikacin and fortune 5 days, nebulizer aerosol by Lasolvan, fistarol, fluimucil, panzytrat 25000 10 capsules per day. The purpose is erektsii severe hypoxemia and hypoxia, in order correction of metabolism and reduce the activity of inflammation conducted a 5-day course of intravenous ozone therapy in ozone concentration 250 µg/l, 1 times a day, a course of 5 days, within 30 minutes, half an hour after traditional therapy. When assigning ozone adverse reactions were not noted positive dynamics of clinical symptoms and laboratory parameters. Temperature returned to normal within days. On day 3 of treatment significantly improved health, normal appetite, increased motor activity, and in the same period of treatment decreased the amount of catarrhal phenomena in the lungs and their prevalence. Indicators of KOS after 5 days of treatment: pH 7,42, pO2- 110, pCO2- 30, BE -(- 2,5), AB - 20, saturated oxygen - 99,7. General an. blood at discharge: HB 132, E. - 4, L - 6,5; p - 1%, C - 70%l - 25%. M - 4%, ESR - 3 mm/h After eight days, the period of exacerbation was stopped and the girl was discharged home.
Our proposed method of treatment of children suffering from cystic fibrosis, technically simple, does not require expensive equipment, can improve the effectiveness of the treatment extremely difficult group of patients. Positive dynamics of clinical symptoms, indicators of gas composition of the blood is high enough to evaluate the possibilities and prospects of additional non-pharmacological treatment of children with severe the th, sometimes fatal diseases. The method significantly improves the quality of care, reduces the duration of treatment of patients, it does not cause acute or chronic side effects.
|Indicators of KOS and blood gases sick So 4 HP (venous blood)|
|Norm drops||Before the treatment||After 5 days of ozone therapy|
|pH||7,32 was 7.45||7,31||7,34|
|O2sat (pulse oximeter)||93%||60,3**||br93.1**|
|** Statistically significant differences|
The method of complex treatment of severe forms of cystic fibrosis in children, including the introduction of traditional medicines, characterized in that it further for 30 min intravenous ozonized physiological solution (ODF) once daily, and for children up to 3 years of COI is lsout ODF with ozone concentration of 100-150 µg/l in 100-150 ml, and for children older than 3 years - ODF with ozone concentration of 200-250 ág/l in 200-250 ml, therapy ODF - 5 days, but traditional drugs are not used within 30 minutes before and after the introduction of ODF.
FIELD: medicine, biochemistry, pharmacy.
SUBSTANCE: invention relates to drugs used in treatment and prophylaxis of diseases associated with deficiency or absence of enzyme lactase in human body. Agent comprises enzyme lactase isolated from cultural fluid of microscopic fungus Penicillium canescens with activity 10000 U/g, not less, and shows stability in the pH range from 2.5 to 7.0 and temperatures from 4°C to 60°C. Agent provides effective cleavage of lactose in milk and dairy foodstuffs to a mixture of easily assimilable monosuccharides: glucose and galactose that results to availability of dairy foodstuffs for their using by humans suffering from lactose intolerance. Enzyme is stable that allows its using both for dosing orally with simultaneous using dairy foodstuffs and for their preliminary treatment.
EFFECT: valuable medicinal and nutrient properties of agent.
2 cl, 2 tbl, 2 dwg, 2 ex
SUBSTANCE: method involves applying dietotherapy containing nutrient fibers at a dose of 10-20 g/day. De-nol is additionally introduced at a dose of 120 mg 3-4 times 30 min before taking meals and Mezyme forte at a dose of 1 tablet 3 times a day while eating.
EFFECT: enhanced effectiveness in normalizing intestinal flora; reduced number of adverse side effects; excluded disease recurrence.
FIELD: medicine, pharmacology, biochemistry, enzymes.
SUBSTANCE: invention relates to an enzyme-containing medicinal agent wherein enzymes are chosen from a group consisting of hydrolases, lipases, amylases, glycosidases, phospholipases, phosphodiesterases, phosphatases prepared from infusoria. Also, invention relates to a method for using indicated enzymes in improving digestion or in treatment of digestion disorders. Invention enhances resistance to stomach acid media and preparing from safety microorganism.
EFFECT: valuable medicinal properties of enzymes.
7 cl, 2 tbl, 7 dwg, 2 ex
FIELD: medicine, surgical oncoproctology.
SUBSTANCE: one should introduce laevomycetin and furasolidon or bactrim and furasolidon 5 d before operation. Then, on the 3d d after operation it is necessary to perorally introduce 300 ml low-methoxylated 1%-pectin extract (LPE) - per 100 ml thrice daily, and then 600 ml - per 200 ml thrice daily, 10 d totally. Starting since the 4th d after operation one should fulfill peroral introduction of sorbed probiotic (SP) per 10 dosages thrice daily for 10 d. Moreover, 1 dosage of SP corresponds to 1·107 bifidobacterial CFU. In 21 d SP introduction mentioned should be repeated. Due to matched dosages and the mode of introduction of medicinal preparations the present innovation provides complex reconstruction of motor-evacuator function of gastrointestinal tract and microecological balance of large intestine and, thus, the prophylaxis of purulent-septic complications in this particular category of patients.
EFFECT: higher efficiency of correction.
2 ex, 3 tbl
FIELD: veterinary, in particular agents for prophylaxis and treatment of gastric diseases in calves.
SUBSTANCE: the fist foremilk of calved in summer cows is collected, filtered, bottled in sterile 1 l vessels and frozen in freezing apparatus at 20-22°C. In winter-spring period foremilk is defrosted and conserved with potassium sorbate in ratio of 2.5 ml of 40 % potassium sorbate solution per 1 l of foremilk.
EFFECT: environment friendly method for stimulation of calves immunity.
SUBSTANCE: method involves treating gastrointestinal tract without drugs, cleaning organism with enema and lavage procedure, per os introducing a set of nutrient substrates and proper microflora metabolism regulators as a complex of bran and vegetable additives being carriers of micro- and macroelements in the following ingredient proportion taken in weight parts. Bran - 72-86, microelements carriers like green tea, sea kale, shelf fungus, agar-agar, wartwort - 2-3, macroelements carriers like sedge grass, nettle, balm - 1.5-2.5; microbiologic fermentation regulators like cardamom, chili, black pepper, red pepper, nutmeg - 1.0-2.0, fermentation initiator (pastry texturizing agent) - 0.2-0.5. Single lavage procedure with appropriate preparation or cleaning vegetable protein enema of 1.5-2 l is applied before introducing nutrient substrates. A course of own microflora cultivation in gastrointestinal tract is carried out by introducing nutrient substrates set and daily volume of liquid in the amount of not less than 30 ml/kg of body weight and 10-20 mg of lactulose.
EFFECT: enhanced effectiveness of treatment; minimized enema-mediated treatment.
3 cl, 3 dwg
FIELD: veterinary medicine.
SUBSTANCE: method involves introducing alcohol-honey extract of milky-wax ripe walnut with farina and glycine added to unit dose liquid twice a day during 6 days at a dose of 0.5 ml per 1 kg of animal weight.
EFFECT: enhanced effectiveness of treatment; accelerated treatment course.
FIELD: medicine, pharmacology, pharmacy.
SUBSTANCE: invention relates to the development of a new medicinal agent representing the complex enzyme preparation with the digestive effect. Agent comprises enzyme pectate lyase providing effective cleavage of vegetable food intercellular substances, in particular, pectin and protopectin that results to formation of the homogenous and easily digestible mass, and promotes to assimilation vegetable food that is not assimilated by human organism that results to the more complete digestion of food, its cleavage and assimilation of nutrient substances. The optimal content of enzyme pectate lyase and pancreatin in a tablet covered by the enterosoluble envelope promotes to the more rapid and complete digestion of food in intestine and shows significant advantages as compared with the known digestive preparations.
EFFECT: improved and valuable properties of agent.
5 cl, 11 tbl
FIELD: veterinary obstetrics.
SUBSTANCE: the method deals with subcutaneous injection of bioglobin (placenta denaturated suspended - PDS) at the quantity of 20 mg/animal/d not earlier that 10 d before calving. The innovation enables to increase quality in preventing the onset of functional dyspepsia in newborn calves and level of total body resistance.
EFFECT: higher efficiency.
20 dwg, 1 ex, 2 tbl
FIELD: veterinary science.
SUBSTANCE: the suggested preparation for treating diarrhea in farm animals youngsters contains bismuth salt in the form of bismuth-potassium ammonium citrate and, additionally, polyethylenoxide, moreover, preferably, it contains 1.5-2.5%-polyethylenoxide solution and 1.5-2.5%-bismuth-potassium ammonium citrate solution. The method for treating diarrhea deals with introducing the above-mentioned preparation once or twice daily for 1-2 d at the dosage of 1-75 ml/kg body weight. In young foxes it should be introduced at the dosage of 60-75 ml/kg body weight, in calves - at the dosage of 1-3 ml/kg body weight, in lambs - at the dosage of 2-3 ml/kg body weight. Application of the present complex preparation and therapeutic method enables to shorten terms of therapy by 1.5-2 times, decreases expenses for therapy by 3-5 times and provides decreased toxicological impact the preparation upon animal body.
EFFECT: higher efficiency of therapy.
6 cl, 3 ex, 2 tbl
FIELD: pharmaceutical industry, in particular mucolytic pharmaceutical agent.
SUBSTANCE: claimed composition contains therapeutically effective amount of bromohexin as active ingredient and sugar, starch and stearinic acid salt as target additives. Pharmaceutical composition is provided in form of tablets.
EFFECT: composition with improved physical and pharmaceutical properties, such as dissolving and active ingredient releasing.
8 cl, 2 tbl, 4 ex
SUBSTANCE: method involves administering Surfactant BL in discrete small doses in addition to traditional therapy. Dose of 75 mg is dissolved in 2.5 ml of physiologic saline and introduced by means of bronchoalveolar nebulizer within 2 h three times at a dose of 25 mg.
EFFECT: enhanced effectiveness in treating pneumonia; prevented bronchial obstructive syndrome occurrence.
SUBSTANCE: inhaler has catalytic burner, fuel balloon 6 containing hydrogen, said balloon being connected to burner, reservoir 15 for inhaling additives such as aromatic substances and/or functioning substances, at least one inlet 2 for oxygen-containing gaseous mixture, preferably for air, and at least one outlet 3 for inhaling mixture containing aromatic substances and/or functioning substances.
EFFECT: increased efficiency and convenient usage of inhaler.
13 cl, 1 dwg
FIELD: medicine, combined therapy.
SUBSTANCE: invention relates to pharmaceutical composition for endothelial tumor treatment containing in therapeutically effective amount antiangiogenic agent such as polypeptide including RGD sequence namely cyclo(Arg-Gly-Asp-Dphe-NmeVal) and tumor necrosis factor TNFα. Also disclosed are kit containing pharmaceutical composition, application of abovementioned pharmaceutical composition and kit, and method for therapy.
EFFECT: agent for effective treatment of endothelial tumors.
15 cl, 16 ex, 8 dwg
FIELD: pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to producing interferon-containing suppositories. Interferon-containing suppository comprises a fatty base, emulsifier and human lyophilized interferon purified from low-molecular and high-molecular components of the definite antiviral activity. Mixture of mono-, di- and triglycerides and saturated fatty acids from coconut oil and palm oil of sort "Vitepsol" H-15 and W-35 taken in equal ratio are used as a fatty base. Distilled monoglycerides taken in the definite ratio are used as an emulsifier. Above describes suppositories retain specific activity and effectiveness in treatment of viral and bacterial diseases for a long time and show stability against mechanical effects.
EFFECT: improved and valuable properties of suppository.
1 tbl, 1 ex